Literature DB >> 11529928

Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease.

S Takeshita1, T Tokutomi, H Kawase, K Nakatani, H Tsujimoto, Y Kawamura, I Sekine.   

Abstract

Matrix metalloproteinases (MMPs) play an important role in the progression of tumour cells and the invasion of inflammatory cells by degrading the extracellular matrix. In the MMP family, MMP-9 gelatinase is thought to contribute to the pathogenesis of inflammatory arteritis by disrupting the elastic lamina. The aim of the present study is to investigate the potential role of MMP-9 in Kawasaki disease (KD), an acute type of systemic vasculitis in children. We studied the total levels of MMP-9 (free proMMP-9 and free MMP-9) in the sera using a new assay system and the expression of MMP-9 mRNA in the leucocytes using reverse transcription-polymerase chain reaction in 18 patients with KD, 10 patients with sepsis and 10 healthy children (HC). The serum MMP-9 levels were significantly higher (P < 0.01) in the acute phase of KD than in the acute phase of sepsis and HC. In the time course of KD, the serum MMP-9 levels decreased significantly (P < 0.01) from the subacute through the convalescent phases. In the acute phase of KD, the serum MMP-9 levels showed a significantly positive correlation (P < 0.05) with the circulating leucocyte counts, especially the neutrophil counts. Furthermore, the expression of MMP-9 mRNA in the circulating leucocytes increased in the acute phase of KD and decreased from the subacute through the convalescent phases. These findings indicate that an excessive amount of MMP-9 is present in the plasma during the acute phase of KD, thus suggesting that circulating leucocytes may be a source of the MMP-9 secreted into the circulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11529928      PMCID: PMC1906124          DOI: 10.1046/j.1365-2249.2001.01608.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators.

Authors:  J Pugin; M C Widmer; S Kossodo; C M Liang; A F Suffredini
Journal:  Am J Respir Cell Mol Biol       Date:  1999-03       Impact factor: 6.914

2.  Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties.

Authors:  Y Okada; T Morodomi; J J Enghild; K Suzuki; A Yasui; I Nakanishi; G Salvesen; H Nagase
Journal:  Eur J Biochem       Date:  1990-12-27

3.  Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions.

Authors:  T Matsubara; S Furukawa; K Yabuta
Journal:  Clin Immunol Immunopathol       Date:  1990-07

4.  Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis.

Authors:  Y T Konttinen; M Ainola; H Valleala; J Ma; H Ida; J Mandelin; R W Kinne; S Santavirta; T Sorsa; C López-Otín; M Takagi
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 5.  Matrix metalloproteinases: a review.

Authors:  H Birkedal-Hansen; W G Moore; M K Bodden; L J Windsor; B Birkedal-Hansen; A DeCarlo; J A Engler
Journal:  Crit Rev Oral Biol Med       Date:  1993

6.  A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.

Authors:  J W Newburger; M Takahashi; A S Beiser; J C Burns; J Bastian; K J Chung; S D Colan; C E Duffy; D R Fulton; M P Glode
Journal:  N Engl J Med       Date:  1991-06-06       Impact factor: 91.245

7.  General pathology of Kawasaki disease. On the morphological alterations corresponding to the clinical manifestations.

Authors:  S Amano; F Hazama; H Kubagawa; K Tasaka; H Haebara; Y Hamashima
Journal:  Acta Pathol Jpn       Date:  1980-09

8.  Enhanced neutrophilic functions in mucocutaneous lymph node syndrome, with special reference to the possible role of increased oxygen intermediate generation in the pathogenesis of coronary thromboarteritis.

Authors:  Y Niwa; K Sohmiya
Journal:  J Pediatr       Date:  1984-01       Impact factor: 4.406

9.  Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase.

Authors:  L A Smedly; M G Tonnesen; R A Sandhaus; C Haslett; L A Guthrie; R B Johnston; P M Henson; G S Worthen
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

10.  Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease.

Authors:  D Y Leung; R S Cotran; E Kurt-Jones; J C Burns; J W Newburger; J S Pober
Journal:  Lancet       Date:  1989-12-02       Impact factor: 79.321

View more
  21 in total

Review 1.  2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease.

Authors:  Frank Zhu; Jocelyn Y Ang
Journal:  Curr Infect Dis Rep       Date:  2021-02-06       Impact factor: 3.725

2.  IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model: Role of Both IL-1α and IL-1β.

Authors:  Youngho Lee; Daiko Wakita; Jargalsaikhan Dagvadorj; Kenichi Shimada; Shuang Chen; Ganghua Huang; Thomas J A Lehman; Michael C Fishbein; Hal M Hoffman; Timothy R Crother; Moshe Arditi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-29       Impact factor: 8.311

3.  Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease.

Authors:  Pong Kian Chua; Marian E Melish; Qigui Yu; Richard Yanagihara; Kara S Yamamoto; Vivek R Nerurkar
Journal:  Clin Diagn Lab Immunol       Date:  2003-03

Review 4.  Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.

Authors:  Jane C Burns; Isabelle Koné-Paut; Taco Kuijpers; Chisato Shimizu; Adriana Tremoulet; Moshe Arditi
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

5.  Sustained activation of neutrophils in the course of Kawasaki disease: an association with matrix metalloproteinases.

Authors:  M H Biezeveld; G van Mierlo; R Lutter; I M Kuipers; T Dekker; C E Hack; J W Newburger; T W Kuijpers
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

6.  Matrix metalloproteinases production in malignant pleural effusions after talc pleurodesis.

Authors:  P D'Agostino; A Rao Camemi; R Caruso; F Arcoleo; A Cascio; A Dolce; E Sacco; G Cangemi; T di Rosa; P Moceo; E Cillari
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

7.  Association of the matrix metalloproteinase-3 (-439C/G) promoter polymorphism with Kawasaki disease in Korean children.

Authors:  Young Mi Hong; Hyun-Seung Jin; In Sook Park; Soo-Jong Hong
Journal:  Heart Vessels       Date:  2008-09-20       Impact factor: 2.037

Review 8.  Kawasaki disease.

Authors:  Dong Soo Kim
Journal:  Yonsei Med J       Date:  2006-12-31       Impact factor: 2.759

9.  Promoter polymorphism (rs3755724, -55C/T) of tissue inhibitor of metalloproteinase 4 (TIMP4) as a risk factor for Kawasaki disease with coronary artery lesions in a Korean population.

Authors:  Ju Yeon Ban; Kyung Leem Yoon; Su Kang Kim; Sungwook Kang; Joo-Ho Chung
Journal:  Pediatr Cardiol       Date:  2008-12-02       Impact factor: 1.655

10.  Late-appearing brachiocephalic aneurysm: an atypical vascular sequella of Kawasaki disease.

Authors:  Gaby Yang; Deborah Thompson; Andrew Warren
Journal:  Pediatr Cardiol       Date:  2008-08-15       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.